Jim Wassil Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 8,000 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $86.22, for a total transaction of $689,760.00. Following the sale, the chief operating officer now directly owns 205,695 shares of the company’s stock, valued at $17,735,022.90. This represents a 3.74 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jim Wassil also recently made the following trade(s):

• On Thursday, January 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $83.66, for a total transaction of $669,280.00.
• On Monday, December 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $92.49, for a total value of $739,920.00.

Vaxcyte Stock Up 3.3 %

Shares of Vaxcyte stock opened at $89.34 on Thursday. Vaxcyte, Inc. has a 12-month low of $58.10 and a 12-month high of $121.06. The business’s 50 day moving average is $87.37 and its 200-day moving average is $94.45. The stock has a market cap of $11.14 billion, a P/E ratio of -19.42 and a beta of 0.98.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same quarter in the prior year, the business earned ($0.91) EPS. On average, sell-side analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its position in Vaxcyte by 68.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 21,466 shares of the company’s stock worth $2,453,000 after buying an additional 8,685 shares during the last quarter. Natixis Advisors LLC increased its holdings in shares of Vaxcyte by 61.1% during the 3rd quarter. Natixis Advisors LLC now owns 22,697 shares of the company’s stock worth $2,594,000 after acquiring an additional 8,606 shares during the last quarter. Diversified Trust Co bought a new stake in Vaxcyte in the 4th quarter valued at $1,433,000. Lisanti Capital Growth LLC raised its stake in Vaxcyte by 68.1% in the 3rd quarter. Lisanti Capital Growth LLC now owns 32,515 shares of the company’s stock valued at $3,715,000 after acquiring an additional 13,175 shares during the period. Finally, WCM Investment Management LLC lifted its holdings in Vaxcyte by 52.6% during the 3rd quarter. WCM Investment Management LLC now owns 140,847 shares of the company’s stock valued at $15,935,000 after purchasing an additional 48,543 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

PCVX has been the subject of a number of research reports. Needham & Company LLC reiterated a “buy” rating and set a $140.00 price objective on shares of Vaxcyte in a report on Wednesday, November 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Finally, The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a research report on Friday, December 20th. They issued a “buy” rating and a $135.00 price objective on the stock. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $145.71.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.